Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Xueliang Wang(Sun Yat-sen University), Y. Q. Fang(Sun Yat-sen University), Wei Liang(Sun Yat-sen University), Chi Chun Wong(Chinese University of Hong Kong), Huanlong Qin(Tongji University), Yaohui Gao(Tongji University), Meinong Liang(Sun Yat-sen University), Lei Song(Sun Yat-sen University), Yongxin Zhang(Sun Yat-sen University), Miao Fan(Sun Yat-sen University), Chuanfa Liu(Chinese University of Hong Kong), Harry Cheuk-Hay Lau(Chinese University of Hong Kong), Lixia Xu(Sun Yat-sen University), Xiaoxing Li(Sun Yat-sen University), Song Wu(Sun Yat-sen University), Junlin Wang(Sun Yat-sen University), Na Wang(Sun Yat-sen University), Tao Yang(Sun Yat-sen University), Mengmiao Mo(Sun Yat-sen University), Xiang Zhang(Chinese University of Hong Kong), Fang Jingyuan(Shanghai Jiao Tong University), Bing Liao(Sun Yat-sen University), Joseph J.�Y. Sung(Chinese University of Hong Kong), Jun Yu(Sun Yat-sen University)
Cited by 182Open Access
Abstract
T cell exhaustion and promoting effector function. Supporting this notion, knockout of a butyric acid-producing gene in Fn abolishes its anti-PD-1 boosting effect. In patients with MSS CRC, high intratumoral Fn predicts favorable response to anti-PD-1 therapy, indicating Fn as a potential biomarker of immunotherapy response in MSS CRC.
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al.|New England Journal of Medicine|2012|12.6k